Truist Financial Forecasts Strong Price Appreciation for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective increased by analysts at Truist Financial from $780.00 to $982.00 in a research note issued to investors on Monday, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Truist Financial‘s price objective suggests a potential upside of 1.42% from the stock’s previous close.

A number of other analysts have also recently weighed in on the company. JPMorgan Chase & Co. boosted their price target on Regeneron Pharmaceuticals from $950.00 to $1,050.00 and gave the stock an “overweight” rating in a research report on Friday. Zacks Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, September 28th. Canaccord Genuity Group raised their price objective on Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the company a “buy” rating in a research note on Wednesday, October 28th. TD Cowen boosted their target price on Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the stock a “buy” rating in a report on Wednesday, October 21st. Finally, Evercore boosted their target price on Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $890.97.

Regeneron Pharmaceuticals Stock Up 4.4%

REGN traded up $40.40 during trading on Monday, reaching $968.29. 637,215 shares of the stock traded hands, compared to its average volume of 821,362. The stock has a market cap of $99.70 billion, a price-to-earnings ratio of 21.35, a price-to-earnings-growth ratio of 1.57 and a beta of 0.10. Regeneron Pharmaceuticals has a fifty-two week low of $591.52 and a fifty-two week high of $972.06. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.06 and a quick ratio of 3.66. The stock’s 50-day simple moving average is $793.30 and its two-hundred day simple moving average is $738.05.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The firm had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $4.58 billion. During the same quarter in the previous year, the company posted $11.83 earnings per share. The business’s quarterly revenue was up 36.3% compared to the same quarter last year. As a group, equities research analysts expect that Regeneron Pharmaceuticals will post 49.10 EPS for the current year.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the completion of the transaction, the director directly owned 603 shares of the company’s stock, valued at approximately $512,550. This trade represents a 39.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 8,093 shares of company stock worth $6,506,845. 6.97% of the stock is owned by company insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Boston Trust Walden Corp boosted its stake in shares of Regeneron Pharmaceuticals by 794.1% in the 3rd quarter. Boston Trust Walden Corp now owns 10,667 shares of the biopharmaceutical company’s stock valued at $8,088,000 after purchasing an additional 9,474 shares in the last quarter. Chicago Partners Investment Group LLC increased its position in shares of Regeneron Pharmaceuticals by 29.7% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 2,865 shares of the biopharmaceutical company’s stock worth $2,306,000 after purchasing an additional 656 shares in the last quarter. Covestor Ltd increased its position in shares of Regeneron Pharmaceuticals by 31.5% during the 3rd quarter. Covestor Ltd now owns 171 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 41 shares in the last quarter. Compass Financial Management LLC lifted its holdings in Regeneron Pharmaceuticals by 4,526.2% during the 3rd quarter. Compass Financial Management LLC now owns 3,007 shares of the biopharmaceutical company’s stock valued at $2,280,000 after purchasing an additional 2,942 shares during the last quarter. Finally, Pzena Investment Management LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $310,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Strong Q3 results: Regeneron reported earnings of $20.07 per share, well above the $16.51 analyst consensus, while revenue rose 36% year over year to approximately $5.1 billion. Earnings growth of about 70%, strong Dupixent sales and a larger Sanofi profit share are reinforcing investor confidence. These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 Results
• Positive Sentiment: Analysts raised targets: Guggenheim lifted its target to $1,100 and initiated a “buy” view, while JPMorgan raised its target to $1,050 with an “overweight” rating. Bank of America increased its target to $1,030 and kept a “buy” rating; broader analyst forecasts reportedly reach as high as $1,175. Regeneron Pharmaceuticals Analyst Forecasts
• Positive Sentiment: Pipeline and commercial momentum: Investors are also responding to the company’s deep pipeline, encouraging Libtayo data in high-risk skin cancer and an expanded BARDA supply agreement for an Ebola treatment. Why Regeneron Shares Are In Focus After Strong Earnings
• Positive Sentiment: Shareholder returns: Regeneron declared a quarterly dividend of $0.94 per share, payable December 3, and continues repurchases under its buyback program.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.